EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies

Danlei Liu iD, Ka-Yi Leung, Ruiqi Zhang, Hoi-Yan Lam, Yujing Fan, Xiaochun Xie, Wan-Mui Chan, Kelvin Kai-Wang To, Kwok-Hung Chan, Ivan Fan-Ngai Hung

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Danlei Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Oseltamivir, Influenza A Virus, H1N1 Subtype, Antiviral Agents, Orthomyxoviridae Infections. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Medical Research Fund 2019-2022 Commissioned Programmes for Influenza Research, Research Grants Council Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza surveillance and drug resistance testing have always been central to clinical efforts. Therefore, researching the virus characteristics and antiviral drugs is essential.

Method

The HA and NA activities were assessed in influenza strains, and mutations were identified through gene sequencing. The effects of oseltamivir, molnupiravir, and baloxavir treatments were evaluated in vitro. The effectiveness of molnupiravir monotherapy and its combination with baloxavir was also evaluated in a mouse model. Changes in body weight and lung tissue were examined, including pathological changes, virus replication, and inflammation levels.

Results

Forty‐one seasonal influenza H1N1 strains from 2023 were used. The EC 50 of oseltamivir was significantly increased compared to the 2009 reference strain. Correlation analysis showed that the increase in EC 50 was related to the HA and NA activities. The antiviral effects of molnupiravir and baloxavir significantly inhibited virus replication; the combination treatment of molnupiravir/baloxavir showed more potent and synergistic inhibitory effects in vitro. In the mouse model, molnupiravir treatment effectively inhibited virus replication and lung inflammation, but the treatment did not improve weight loss or reduce mortality. With the molnupiravir/baloxavir treatment, viral replication was significantly inhibited and proved to be more effective than either monotherapy. The combination therapy also showed the lowest inflammatory response along with a higher survival rate.

Conclusions

The increase in HA and NA activities of seasonal influenza reduced the efficacy of oseltamivir treatment, but the effectiveness of molnupiravir and baloxavir was retained. Combination therapy showed a significant antiviral effect, which provides a reference for the clinical treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirInfluenza A Virus, H1N1 SubtypeAntiviral AgentsOrthomyxoviridae InfectionsAnimalsMiceVirus ReplicationTriazinesDibenzothiepinsDrug Therapy, CombinationDisease Models, AnimalHumansInfluenza, HumanPyridonesFemaleThioureaMorpholinesHydroxylaminesMice, Inbred BALB CLungPyridinesDrug Resistance, ViralCytidine

Stichwörter der Autor:innen

antiviral treatmenthemagglutinininfluenzaneuraminidase

Substanzen

OseltamivirAntiviral AgentsbaloxavirTriazinesDibenzothiepinsmolnupiravirPyridonesThioureaMorpholinesHydroxylamines

Autor:innen und Institutionen

  • Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Department of Microbiology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • State Key Laboratory for Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China.

ORCID-Profile: Danlei Liu

Förderung

  • Health and Medical Research Fund 2019-2022 Commissioned Programmes for Influenza Research
  • Research Grants Council Research Fund

Zitieren

APA

Liu, D., Leung, K. Y., Zhang, R., Lam, H. Y., Fan, Y., Xie, X., Chan, W. M., To, K. K., Chan, K. H., & Hung, I. F. (2025). Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70176

Vancouver

Liu D, Leung KY, Zhang R, Lam HY, Fan Y, Xie X, et al. Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70176

BibTeX
@article{Liu2025,
  author = {Liu, Danlei and Leung, Ka-Yi and Zhang, Ruiqi and Lam, Hoi-Yan and Fan, Yujing and Xie, Xiaochun and Chan, Wan-Mui and To, Kelvin Kai-Wang and Chan, Kwok-Hung and Hung, Ivan Fan-Ngai},
  title = {Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70176}
}
Kostenlos starten →